[{"id":"8071c405-9b54-4ff6-82e5-09e8fad7fb2c","acronym":"T-LGLL","url":"https://clinicaltrials.gov/study/NCT05141682","created_at":"2021-12-02T18:54:30.785Z","updated_at":"2025-02-25T12:38:03.521Z","phase":"Phase 1/2","brief_title":"Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia","source_id_and_acronym":"NCT05141682 - T-LGLL","lead_sponsor":"Jonathan Brammer","biomarkers":" CD8","pipe":" | ","alterations":" STAT3 mutation","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Onureg (azacitidine oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/29/2022","start_date":" 06/29/2022","primary_txt":" Primary completion: 08/15/2024","primary_completion_date":" 08/15/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"da3b2b09-ed01-4312-97c2-dda82f0fd6ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04799275","created_at":"2021-03-16T18:52:53.431Z","updated_at":"2025-02-25T13:53:42.140Z","phase":"Phase 2/3","brief_title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04799275","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • CD4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 422","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-20"},{"id":"f5056d6b-3ffd-4e44-961f-b461e0552213","acronym":"A051902","url":"https://clinicaltrials.gov/study/NCT04803201","created_at":"2021-03-17T15:57:46.362Z","updated_at":"2025-02-25T14:15:53.168Z","phase":"Phase 2","brief_title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT04803201 - A051902","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-18"},{"id":"460f1e61-72a2-48bb-a37c-e804016f6240","acronym":"NCI-2021-06095","url":"https://clinicaltrials.gov/study/NCT05010122","created_at":"2021-08-18T15:53:42.501Z","updated_at":"2025-02-25T15:12:15.219Z","phase":"Phase 1/2","brief_title":"ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05010122 - NCI-2021-06095","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/08/2021","start_date":" 07/08/2021","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-13"},{"id":"f2c492b8-d008-47fb-bfe0-8880113c29ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT06113289","created_at":"2023-11-02T15:12:40.366Z","updated_at":"2025-02-25T15:21:01.496Z","phase":"Phase 1/2","brief_title":"A Phase 1B/2A Trial of Combination of ASTX727 with ASTX029 in Acute Myeloid Leukemia","source_id_and_acronym":"NCT06113289","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • NF1 • PTPN11","pipe":"","alterations":" ","tags":["KRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • beroterkib anhydrous (ASTX029)"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 02/08/2024","start_date":" 02/08/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-12"},{"id":"161e5bfa-d426-464a-9703-09d1a3988f05","acronym":"","url":"https://clinicaltrials.gov/study/NCT05600894","created_at":"2022-11-05T15:14:14.733Z","updated_at":"2025-02-25T16:39:25.353Z","phase":"Phase 2","brief_title":"Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm","source_id_and_acronym":"NCT05600894","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 06/27/2023","start_date":" 06/27/2023","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-07"},{"id":"67917d6a-e1b0-409b-853a-7e9fd258dd6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06802523","created_at":"2025-02-25T16:34:56.075Z","updated_at":"2025-02-25T16:34:56.075Z","phase":"Phase 1","brief_title":"Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT06802523","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine) • Actimab-A (lintuzumab-Ac225)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-07"},{"id":"aa4d2f71-0b09-413a-abc9-1d8702d772bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065866","created_at":"2021-10-04T12:53:00.645Z","updated_at":"2025-02-25T16:45:37.143Z","phase":"Phase 1","brief_title":"Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy","source_id_and_acronym":"NCT05065866","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 11/18/2021","start_date":" 11/18/2021","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-06"},{"id":"646a5bb4-c6c5-49c4-b475-0738f83491e5","acronym":"NCI-2021-02246","url":"https://clinicaltrials.gov/study/NCT04817241","created_at":"2021-03-26T15:52:34.807Z","updated_at":"2025-02-25T17:00:59.840Z","phase":"Phase 1/2","brief_title":"Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients","source_id_and_acronym":"NCT04817241 - NCI-2021-02246","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • daunorubicin • Inqovi (decitabine/cedazuridine) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/10/2022","start_date":" 02/10/2022","primary_txt":" Primary completion: 10/25/2025","primary_completion_date":" 10/25/2025","study_txt":" Completion: 10/25/2025","study_completion_date":" 10/25/2025","last_update_posted":"2025-02-03"},{"id":"879fd467-51b3-46e4-9863-a9475f8f4f72","acronym":"Oracle","url":"https://clinicaltrials.gov/study/NCT03593018","created_at":"2021-01-18T17:39:39.095Z","updated_at":"2025-02-25T14:27:18.930Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL","source_id_and_acronym":"NCT03593018 - Oracle","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • azacitidine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/09/2018","start_date":" 11/09/2018","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-10-09"},{"id":"ade707b7-5e5b-4f00-a824-2c91c94d8afe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04578600","created_at":"2021-01-18T21:51:14.278Z","updated_at":"2025-02-25T14:29:38.782Z","phase":"Phase 1","brief_title":"CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma","source_id_and_acronym":"NCT04578600","lead_sponsor":"Joseph Tuscano","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Gazyva (obinutuzumab) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-09-19"},{"id":"752adfe9-ab45-4296-93ce-d79ee99fa87f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05007873","created_at":"2022-04-24T09:03:10.634Z","updated_at":"2025-02-25T16:26:40.003Z","phase":"Phase 2","brief_title":"ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase","source_id_and_acronym":"NCT05007873","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 10/30/2026","primary_completion_date":" 10/30/2026","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2024-08-27"},{"id":"8357d385-35ac-4d87-9fa3-47078a947c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT02650986","created_at":"2021-01-18T12:54:24.654Z","updated_at":"2024-07-02T16:34:26.492Z","phase":"Phase 1/2","brief_title":"Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1","source_id_and_acronym":"NCT02650986","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" BRAF • CTAG1B","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • cyclophosphamide • decitabine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/14/2017","start_date":" 07/14/2017","primary_txt":" Primary completion: 03/04/2021","primary_completion_date":" 03/04/2021","study_txt":" Completion: 07/14/2032","study_completion_date":" 07/14/2032","last_update_posted":"2024-06-13"},{"id":"aa92e647-2204-49a9-b0eb-03d672654c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT05037500","created_at":"2021-09-08T14:53:05.286Z","updated_at":"2024-07-02T16:34:27.381Z","phase":"Phase 1","brief_title":"Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer","source_id_and_acronym":"NCT05037500","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" TP53 • RB1","pipe":"","alterations":" ","tags":["TP53 • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/26/2022","start_date":" 01/26/2022","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2024-06-11"},{"id":"566dbbb6-eabe-4dfb-be9c-7161bcda7964","acronym":"","url":"https://clinicaltrials.gov/study/NCT05960773","created_at":"2023-07-27T18:08:58.951Z","updated_at":"2024-07-02T16:34:37.145Z","phase":"Phase 2","brief_title":"Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma","source_id_and_acronym":"NCT05960773","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/31/2024","start_date":" 01/31/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-07"},{"id":"068c80f1-b744-42e6-bb47-84aa54ab2e3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05673200","created_at":"2023-01-06T16:59:14.142Z","updated_at":"2024-07-02T16:34:38.142Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05673200","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • paclitaxel • Inqovi (decitabine/cedazuridine) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 24","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 02/23/2027","primary_completion_date":" 02/23/2027","study_txt":" Completion: 02/23/2027","study_completion_date":" 02/23/2027","last_update_posted":"2024-06-05"},{"id":"5f6cead8-271a-4f4a-b549-d12536680be3","acronym":"ETCTN","url":"https://clinicaltrials.gov/study/NCT04340843","created_at":"2023-11-13T22:14:48.481Z","updated_at":"2024-07-02T16:35:03.396Z","phase":"Phase 2","brief_title":"Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma","source_id_and_acronym":"NCT04340843 - ETCTN","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":"","alterations":" ","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • Beleodaq (belinostat) • guadecitabine (SGI-110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/08/2020","start_date":" 09/08/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-16"},{"id":"862eb385-171b-4581-9e17-fb92dd0e69c0","acronym":"AMADEUS","url":"https://clinicaltrials.gov/study/NCT04173533","created_at":"2021-01-18T20:21:37.079Z","updated_at":"2024-07-02T16:35:03.802Z","phase":"Phase 3","brief_title":"Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT","source_id_and_acronym":"NCT04173533 - AMADEUS","lead_sponsor":"University of Birmingham","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 326","initiation":"Initiation: 06/14/2019","start_date":" 06/14/2019","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-05-14"},{"id":"2291eab5-9fb4-44d5-96f0-82bfe5388eb5","acronym":"GFM-DACORAL-DLI","url":"https://clinicaltrials.gov/study/NCT04857645","created_at":"2021-04-23T21:52:37.777Z","updated_at":"2024-07-02T16:35:11.776Z","phase":"Phase 2","brief_title":"ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients","source_id_and_acronym":"NCT04857645 - GFM-DACORAL-DLI","lead_sponsor":"Groupe Francophone des Myelodysplasies","biomarkers":" TP53 • RUNX1 • ASXL1","pipe":" | ","alterations":" RUNX1 mutation","tags":["TP53 • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-04-03"},{"id":"7737d144-a404-4582-aab1-5735a517fdd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206047","created_at":"2021-01-18T15:48:08.496Z","updated_at":"2024-07-02T16:35:11.758Z","phase":"Phase 1/2","brief_title":"Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03206047","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CTAG1B","pipe":" | ","alterations":" PD-L1 expression • CTAG1B expression","tags":["PD-L1 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Hiltonol (poly-ICLC) • guadecitabine (SGI-110) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-04-03"},{"id":"be88f98e-0fa1-4b42-a319-2f05034b56b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922555","created_at":"2021-01-18T19:17:53.739Z","updated_at":"2024-07-02T16:35:12.305Z","phase":"Phase 1","brief_title":"ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas","source_id_and_acronym":"NCT03922555","lead_sponsor":"Massachusetts General Hospital","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/12/2019","start_date":" 07/12/2019","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-03-29"},{"id":"241b310b-ed13-4033-b928-505add39916c","acronym":"NCI-2016-00343","url":"https://clinicaltrials.gov/study/NCT02684162","created_at":"2021-01-18T13:05:26.435Z","updated_at":"2024-07-02T16:35:12.965Z","phase":"Phase 2","brief_title":"Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant","source_id_and_acronym":"NCT02684162 - NCI-2016-00343","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e guadecitabine (SGI-110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 06/22/2016","start_date":" 06/22/2016","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-25"},{"id":"f73911e5-e1de-4e1b-ac56-12e2040f406e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04134884","created_at":"2021-01-18T20:11:32.856Z","updated_at":"2024-07-02T16:35:13.096Z","phase":"Phase 1","brief_title":"Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer","source_id_and_acronym":"NCT04134884","lead_sponsor":"Kathy Miller","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 04/01/2020","start_date":" 04/01/2020","primary_txt":" Primary completion: 01/30/2024","primary_completion_date":" 01/30/2024","study_txt":" Completion: 03/14/2024","study_completion_date":" 03/14/2024","last_update_posted":"2024-03-22"},{"id":"8e9016c5-f335-427f-9f26-0ca96ab2e497","acronym":"LANTana","url":"https://clinicaltrials.gov/study/NCT05178693","created_at":"2022-01-05T12:53:41.791Z","updated_at":"2025-02-25T15:54:18.184Z","phase":"Phase 1","brief_title":"Lutathera and ASTX727 in Neuroendocrine Tumours","source_id_and_acronym":"NCT05178693 - LANTana","lead_sponsor":"Imperial College London","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/25/2022","start_date":" 04/25/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-20"}]